Synlogic Inc · OTC:SYBX

Synlogic — Q4 2020 Earnings Presentation

18 slides from Synlogic's earnings presentation, Mar 25, 2021

  1. Slide 1: Q4 Financial Results & Business Update

    Bringing the Transformative Power of Synthetic Biology to Medicine Q4 Financial Results & Business Update 25 March 2021 Exhibit 99.2

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Opening Remarks

    © 2020 SYNLOGIC. QU©AR2T0E1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 33 Opening Remarks Dr. Aoife Brennan MB CHB President & CEO

  4. Slide 4: Recent highlights: Execution across the portfolio

    SYNB1891 in Solid Tumors Monotherapy demonstrated target engagement, meaningful pharmaco-dynamic effects, good safety Combination with anti-PD1 and continued dose escalation ongoing Metabolic programs: Two PoC opportunities Immunomodulation Recent highlights: Execution across the portfolio 2021 data

  5. Slide 5: Robust pipelines with meaningful catalysts

    Exploratory Preclinical IND-Enabling Studies Phase 1 Phase 2 Phenylketonuria (PKU) SYNB1618 Vaccines & Other Inflammatory Immuno-Oncology (IO) Solid Tumors SYNB1891 Inflammatory Bowel Disease Enteric Hyperoxaluria SYNB8802 SYNB1618 Undisclosed Metabolic Program #1 Undisclosed Metabolic Program #2 Po

  6. Slide 6: Progress in Metabolic Programs

    © 2020 SYNLOGIC. QUARTERLY RESULTS. ALL RIGHTS RESERVED. | 9 Progress in Metabolic Programs Dr. Richard Riese, MD, PhD Chief Medical Officer

  7. Slide 7: Enteric Hyperoxaluria (HOX)

    Enteric Hyperoxaluria (HOX) Enteric Hyperoxaluria results in significant, irreversible, and progressive kidney damage SYNB8802 offers potential for best-in-class urinary oxalate lowering SYNB8802 proof of concept study on track for 2021 data read out

  8. Slide 8: Ph1 design provides POC opportunity in 2021

    Ph1 design provides POC opportunity in 2021 Dietary hyperoxaluria model is translationally relevant to patient population Phase 1A Dietary Hyperoxaluria (Healthy Volunteers) Multiple Ascending Dose High oxalate & low calcium diet run-in Induce dietary hyperoxaluria N = 45 subjects Endpoints Primary:

  9. Slide 9: High oxalate diet successfully elevated UOx levels in HV

    High oxalate diet successfully elevated UOx levels in HV Historically Uox in HV is <40 mg/24h. Examples: Langman 2018, (27 mg), Quintero 2020, (19.8mg), Captozyme 2018 (28 mg). Mean +/- SD shown. American diet contains approx. 200-250 mg oxalate/day HV subjects were given a high oxalate, low calcium

  10. Slide 10: Dose-responsive and reproducible Uox lowering demonstrated

    Dose-responsive and reproducible Uox lowering demonstrated Efficacy Analysis (% Change from Baseline in 24h UOx over Pbo) 600mg Daily Oxalate 400mg Daily Oxalate Lower is better Lower is better LS mean change over Placebo, +/- 90% CI, all days baseline and treated

  11. Slide 11: SYNB8802 3e11 live cells dose advancing to Ph1B in patients

    SYNB8802 3e11 live cells dose advancing to Ph1B in patients LS mean change over Placebo, +/- 90% std error of measurement, all days; and 24hr UOx after 5 days of dosing, +/- 90% std error of measurement. 600mg daily oxalate. Change in UOx UOx Levels Urinary oxalate lowering demonstrated at a well to

  12. Slide 12: Opportunity for multiple clinically relevant outcomes in Phase1B

    Opportunity for multiple clinically relevant outcomes in Phase1B Potential to demonstrate meaningful urinary oxalate lowering in patients with active disease Learning opportunities in Phase 1 SYNB8802 has established urinary oxalate lowering in dietary hyperoxaluria (HV) model Potential for urinary

  13. Slide 13: SYNB8802 Summary: 3e11 live cells moving into patients

    SYNB8802 Summary: 3e11 live cells moving into patients SYNB8802 was generally well tolerated in healthy volunteers. No serious or systemic adverse events. Most frequent AEs mild or moderate, transient, and GI-related Dose responsive changes in urinary oxalate levels were observed with a significant

  14. Slide 14: Phenylketonuria (PKU)

    Phenylketonuria (PKU) Current and emerging treatment options leave many patients behind SYNB1618 demonstrates potential to lower Phe in PKU patients Phase 2 Phe-lowering trial initiated

  15. Slide 15: SynPheny POC Study in PKU

    SynPheny POC Study in PKU Study powered for 20% reduction in labelled plasma Phe, providing clinically meaningful endpoint for patients without other treatment options Reduction in labelled plasma Phe after a meal challenge, not influenced by diet Reduction in fasting plasma Phe (on treatment relati

  16. Slide 16: 4th Quarter and Year End 2020 Summary Results

    Balance Sheet (unaudited) 31 Dec 2020 31 Dec 2019 Cash, Cash Equivalents, and Marketable Securities $100.4 M $127.1M Statement of Operations (unaudited) 31 Dec 2020 31 Dec 2019 31 Dec 2020 31 Dec 2019 R&D Expenses $11.4 M $11.3 M $47.5 M $41.9 M G&A Expenses $3.3 M $3.5 M $13.5 M $14.7 M Net Loss $(

  17. Slide 17: Concluding Remarks

    © 2020 SYNLOGIC. QU©AR2TE1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 1414 Concluding Remarks Dr. Aoife Brennan MD CHB President & CEO

  18. Slide 18: Available For Questions

    Available For Questions Dave Hava, PhD Chief Scientific Officer Caroline Kurtz, PhD Chief Development Officer Daniel Rosan Head of Finance & Investor Relations Aoife Brennan, MB ChB President & CEO Richard Riese, MD PhD Chief Medical Officer Antoine Awad Chief Operating Officer Gregg Beloff, JD MBA

Synlogic — Q4 2020 Earnings Presentation on 6ix